ReviewFrontiers in immunology2026
Unveiling natural anti-inflammatory compounds for sinusitis treatments by modulating FOXP3, C5aR1, and LIF.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis (CRS) is a condition with a significant healthcare and economic burden, with a prevalence of 12% in the West. The existing therapies mainly attenuate downstream inflammatory mediators but do not address the underlying immune-regulatory abnormalities that drive disease recurrence and lifelong treatment. Evidence has shown that a regulatory axis involving forkhead box P3 (FOXP3) + regulatory T cells (Tregs), the complement component 5a receptor 1 (C5aR1), and leukemia inhibitory factor (LIF) is crucial for regulating immune tolerance in sinonasal tissues. This review discusses the mechanistic basis for modulating FOXP3, C5aR1, and LIF with natural anti-inflammatory products for the treatment of CRS. A comprehensive literature review across PubMed, Scopus, and Web of Science (2000-2026) was conducted to identify research articles on the molecular mechanisms, preclinical evidence, and clinical application of natural compounds in inflammatory disorders and the sinonasal inflammatory pathway. Various studies show that FOXP3+ Tregs are highly depleted in CRS with nasal polyps. Besides, complement signaling via C5aR1 prevents active Treg induction by activating the PI3K-AKT-mTOR pathway. LIF enhances the expression of FOXP3 and opposes Th17 polarization caused by IL-6. Natural products such as epigallocatechin-3-gallate, curcumin, and rosmarinic acid regulate pathways by inhibiting DNA methyltransferases, the complement cascade, and JAK-STAT signaling. Bromelain and cineole have clinical evidence in favor of efficacy in acute sinusitis, and other compounds are showing emerging evidence. The FOXP3-C5aR1-LIF axis is a mechanistic therapeutic target that is largely overlooked by the current biologics. Natural compounds offer potential benefits, including multi-target activity, favorable safety profiles, and the ability to modulate the upstream immune system. Phenotype-based CRS populations should be studied in well-designed trials, bioavailability formulations should be optimized, and synergistic combinations should be systematically explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.